TNFSF10 and glioblastoma: To investigate if CDK inhibition either alone or in combination with TRAIL represents an important potential future therapeutic strategy for GBM patients, we treated human GBM neurospheres with seliciclib (30 μM) and drozitumab (10 μg/mL), either alone or in combination.